Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Lyell Immunopharma (LYEL) Accumulated Depreciation & Amortization (2019 - 2025)

Lyell Immunopharma's Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $19.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 3.06% year-over-year to $19.6 million; the TTM value through Dec 2024 reached $19.6 million, down 3.06%, while the annual FY2024 figure was $19.6 million, 3.06% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $19.6 million at Lyell Immunopharma, down from $20.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $20.2 million in Q4 2023 and bottomed at $4.3 million in Q4 2020.
  • The 5-year median for Accumulated Depreciation & Amortization is $18.0 million (2022), against an average of $15.2 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 241.88% in 2020 before it dropped 3.06% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $4.3 million in 2020, then surged by 217.28% to $13.6 million in 2021, then soared by 32.27% to $18.0 million in 2022, then rose by 12.38% to $20.2 million in 2023, then fell by 3.06% to $19.6 million in 2024.
  • Per Business Quant, the three most recent readings for LYEL's Accumulated Depreciation & Amortization are $19.6 million (Q4 2024), $20.2 million (Q4 2023), and $18.0 million (Q4 2022).